Nuvectis Pharma, Inc..
NVCT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for serious unmet medical needs in oncology. The company's pipeline includes drug candidates targeting various cancer pathways and mechanisms. Nuvectis Pharma is involved in preclinical and clinical devel...Show More
Better Health for All
-10
Nuvectis Pharma is a biopharmaceutical company entirely focused on developing novel therapies for various cancers, including advanced solid tumors, breast cancer, ovarian cancer, cholangiocarcinoma, and NSCLC, addressing unmet medical needs.
1
Its entire business is devoted to health improvement, with products like NXP900 and NXP800 in Phase 1/1b clinical trials.
2
The company has no revenue from harmful products, having been founded in 2016.
3
Two clinical studies for NXP900 have been completed, with an acceptable safety profile and no Dose Limiting Toxicity identified up to 300 mg/day.
4
However, common adverse events reported in the NXP900-101 study (N=33) included diarrhea (45%), fatigue (45%), and nausea (36%), mostly Grade 1-2.
5
The company targets patients with advanced solid tumors, including those with resistance to prior treatments, and has enrolled patients who had a median of 5 prior lines of anticancer treatment.
6
Clinical trials are registered on clinicaltrials.gov, and adverse events are reported, but the company also includes forward-looking statements with disclaimers about risks and uncertainties described in SEC filings.
7
The company leverages internal expertise and established platforms for discovery and optimization of novel therapeutic agents, and NXP900 was discovered at the University of Edinburgh.
8
Clinical trials are actively managed from design to regulatory interactions, but specific ethical frameworks beyond standard registration are not detailed.
9
Fair Money & Economic Opportunity
0
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing therapies in oncology.
1
Its core business does not involve offering lending, deposit services, or other financial products to consumers.
2
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial products, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to the company's operations.
3
Fair Pay & Worker Respect
0
The provided articles contain general corporate governance guidelines and a code of business conduct and ethics, outlining principles for fair dealing and ethical conduct.
1
The CEO's total compensation for 2024 was reported as $1,157,639.
2
However, no specific quantitative data or metrics were found regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, employee turnover rates, labor violation incidents, insecure contract share, or health insurance coverage for the workforce.
3
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend was found for Nuvectis Pharma, Inc.
1
The provided documents, including the company's Code of Business Conduct and Ethics, outline general principles of fair dealing and legal compliance but do not offer measurable data points relevant to the specified KPIs.
2
Honest & Fair Business
-40
Nuvectis Pharma has established procedures for the confidential and anonymous submission of complaints regarding accounting, internal controls, and auditing matters, with a policy to report suspected violations to the Chairman of the Audit Committee.
1
The company's Code of Business Conduct and Ethics explicitly addresses anti-corruption and anti-bribery, emphasizing compliance with FCPA and other relevant laws.
2
Independent auditors are required, and their independence is to be reviewed by the Audit Committee.
3
Kind to Animals
-40
Nuvectis Pharma, Inc. utilizes animal studies for drug discovery and preclinical development.
1
Specifically, the drug compound NXP900 was discovered using studies with mice, and NXP900 and NXP800 have undergone testing in xenograft models of breast and endometrial cancer, respectively, involving in vivo data.
2
While the company's Code of Business Conduct and Ethics emphasizes general ethical standards, it does not contain a specific animal testing policy.
3
The absence of a stated policy, coupled with documented animal testing, indicates a lack of formal guidelines or restrictions on animal use.
No War, No Weapons
0
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on oncology precision medicines, developing drug candidates such as NXP800 and NXP900 for cancer treatment.
1
The provided articles contain no evidence of the company's involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' value.
2
Consequently, all relevant KPIs are scored as N/A, indicating no defense or arms-related activities in its core business or operations.
Planet-Friendly Business
-30
The company's Form 10-K for the period ending December 31, 2024, reported no specific regulatory actions, violations, fines, or compliance issues.
1
The Code of Business Conduct and Ethics states the company's commitment to comply with all applicable environmental laws and regulations.
2
Respect for Cultures & Communities
0
No evidence available to assess Nuvectis Pharma, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess Nuvectis Pharma, Inc. against any of the 'Safe & Smart Tech' KPIs. The articles discuss general industry trends in AI and drug discovery, partnerships, and financial information, but do not provide details on the company's data protection, cybersecurity investments, AI ethics governance, privacy certifications, security training, encryption implementation, audit practices, algorithmic transparency, data use incidents, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy. Article 2, the company's privacy policy, outlines data collection practices and a general security disclaimer but lacks specific, measurable facts relevant to the KPIs.
1
Zero Waste & Sustainable Products
0
No specific, concrete evidence regarding Nuvectis Pharma, Inc.'s waste diversion rate, product recyclability, packaging sustainability, recycled content percentage, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1
The articles either explicitly stated no information was available or were placeholders.